International perspectives on suboptimal patient-reported outcome trial design and reporting in cancer clinical trials: A qualitative study.
cancer
patient-reported outcomes
protocol
qualitative
reporting
trials
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
26
04
2021
accepted:
04
06
2021
pubmed:
6
7
2021
medline:
19
2
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
Evidence suggests that the patient-reported outcome (PRO) content of cancer trial protocols is frequently inadequate and non-reporting of PRO findings is widespread. This qualitative study examined the factors influencing suboptimal PRO protocol content, implementation, and reporting, and use of PRO data during clinical interactions. Semi-structured interviews were conducted with four stakeholder groups: (1) trialists and chief investigators; (2) people with lived experience of cancer; (3) international experts in PRO cancer trial design; (4) journal editors, funding panelists, and regulatory agencies. Data were analyzed using directed thematic analysis with an iterative coding frame. Forty-four interviews were undertaken. Several factors were identified that could influenced effective integration of PROs into trials and subsequent findings. Participants described (1) late inclusion of PROs in trial design; (2) PROs being considered a lower priority outcome compared to survival; (3) trialists' reluctance to collect or report PROs due to participant burden, missing data, and perceived reticence of journals to publish; (4) lack of staff training. Strategies to address these included training research personnel and improved communication with site staff and patients regarding the value of PROs. Examples of good practice were identified. Misconceptions relating to PRO methodology and its use may undermine their planning, collection, and reporting. There is a role for funding, regulatory, methodological, and journalistic institutions to address perceptions around the value of PROs, their position within the trial outcomes hierarchy, that PRO training and guidance is available, signposted, and readily accessible, with accompanying measures to ensure compliance with international best practice guidelines.
Identifiants
pubmed: 34219395
doi: 10.1002/cam4.4111
pmc: PMC8366078
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5475-5487Subventions
Organisme : Macmillan Cancer Support
Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Health Qual Life Outcomes. 2019 Oct 16;17(1):156
pubmed: 31619266
Ther Innov Regul Sci. 2018 Mar;52(2):220-229
pubmed: 29714515
BMJ Open. 2018 Feb 3;8(2):e017282
pubmed: 29431123
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Eur J Cancer. 2016 Mar;56:144-161
pubmed: 26851406
Ann Oncol. 2015 Sep;26(9):1966-1973
pubmed: 26133966
Res Involv Engagem. 2016 Apr 1;2:13
pubmed: 29062514
Patient. 2012;5(2):79-87
pubmed: 22428752
Contemp Clin Trials. 2015 Jul;43:1-9
pubmed: 25896116
Rev Panam Salud Publica. 2015 Dec;38(6):506-14
pubmed: 27440100
Eur J Cancer. 2014 Sep;50(14):2432-48
pubmed: 25034656
J Clin Oncol. 2018 Sep 11;:JCO2018788620
pubmed: 30204536
Qual Life Res. 2018 Oct;27(10):2581-2591
pubmed: 29915979
BMJ. 2001 May 5;322(7294):1115-7
pubmed: 11337448
Clin Trials. 2018 Dec;15(6):624-630
pubmed: 30141714
JAMA. 2018 Feb 6;319(5):483-494
pubmed: 29411037
Cancer Med. 2021 Aug;10(16):5475-5487
pubmed: 34219395
J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178
pubmed: 30959516
Blood. 2018 Jun 28;131(26):2906-2914
pubmed: 29739753
BMJ Open. 2016 Jun 15;6(6):e010938
pubmed: 27311907
BMC Health Serv Res. 2017 Sep 8;17(1):635
pubmed: 28886742
Patient Prefer Adherence. 2016 Apr 27;10:631-40
pubmed: 27175063
Contemp Clin Trials Commun. 2017 Nov 23;9:23-32
pubmed: 29696221
Qual Life Res. 2016 Oct;25(10):2457-2465
pubmed: 27294435
Lancet Oncol. 2018 May;19(5):e267-e274
pubmed: 29726391
Cancer. 2015 Sep 15;121(18):3335-42
pubmed: 26079197
Med Care. 2012 Dec;50(12):1060-70
pubmed: 22922434
N Engl J Med. 2013 Aug 1;369(5):397-400
pubmed: 23822654
JAMA. 2013 Feb 27;309(8):814-22
pubmed: 23443445
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
BMJ. 2019 Jan 24;364:k5267
pubmed: 30679170